Transparency Market Research Report Added "Cerebral Infarction (Brain Infarction) Market" to its database.
Albany, NY -- (SBWIRE) -- 07/29/2016 -- Cerebral Infarction (Brain Infarction) Market: Overview
Brain infarction, also known as, cerebral infarction, is one of the chronic and life-threatening diseases. Cerebral infarction is one of the important type of ischemic stroke which is caused due to the development of blockage or clot in the blood vessel that carry blood to the brain. It is important to highlight that the cerebral infarction is different from brain hemorrhage. Since the disease condition arises suddenly, there is high possibility of death.
The major symptoms of the disease are identified with the help of brain monitoring technology. These symptoms primarily include light reaction, abnormal pupil dilation, loss of eye movement, slurrish speech, loss of energy and loss of movements and senses. The factors that propel the cerebral infarction include diabetes, atherosclerosis, obesity, smoking, blood pressure and others. The diagnosis of the disease is possible through MRI scanning, CT scans, and angiogram.
Cerebral Infarction (Brain Infarction) Market: Segmentation
The market for cerebral infarction is segmented on the basis of types of disease, such as, partial anterior circulation infarct (PACI), total anterior circulation infarct (TACI), posterior circulation infarct (POCI). Further, the market is also segmented on the basis of treatments, such as, anti-myocardial infarction drugs, thrombolytic drugs and others. Thrombolytic drugs such as tissue plasminogen activator (tPA) have proved their effectiveness in the management of the disease. Other treatments include treatment of the root cause of brain infarction, such as, anti-diabetes drugs, blood pressure drugs and others. Carotid endarterectomy is an important surgical treatment available for brain infarction management.
In addition to this, associated treatment includes physical therapy, exercises, speech therapy and angioplasty. Moreover, the market is also segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to extensive research practices and growing prevalence of brain disorders. However, Asia-Pacific and some countries in RoW region are expected to show lucrative growth in upcoming period, owing to enhanced governmental support for research purposes and growth in awareness about neurological diseases.
Cerebral Infarction (Brain Infarction) Market: Trends and Outlook
The market of brain infarction is expected to show promising growth during the forecast period 2014 – 2020. This growth is driven by the various factors, such as, rising prevalence of brain disorders, rising prevalence of the diseases that augment cerebral infarction, extensive R&D practices, rising awareness and medical expenditure of the global population and technological advancements. Ischemic stroke is considered as the most important disease that causes brain infarction. According to the U.S. National Heart, Lung and Blood Institute (NHLBI), 1 in 59 or approximately 4.6 million people in the U.S. are suffering from cardiac stroke disease, which may lead to brain infarction. Out of this, approximately 62% of the cases occur with the patient with high blood pressure.
Download Free exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13232
Thus, the rising prevalence of brain and other associated diseases is expected to propel the market of brain infarction. In addition to this, extensive R&D practices is another important driver of the market. As of 2014, there are number of products under pipeline studies, such as, CNTO-0007, epoetin alfa, AP-102, and others. Major restraints include high cost of R&D, diagnosis and treatment of the disease and limited technological penetration in certain region of the world, such as, Latin America and some of the African countries. These restraints may produce the hurdles to growth of the market.
Major players engaged in R&D and commercialization of products include CIMAB S.A., Johnson & Johnson, Aprogen, Inc., and Shin Nippon Biomedical Laboratories, Ltd. amongst others.
The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape.
Transparency Market Research
90 State Street,
NY - 12207
USA - Canada Toll Free 866-552-3453